ask our doctors

Glucose 6 Phosphate Dehydrogenase Deficiency

Get the facts on Glucose 6 Phosphate Dehydrogenase Deficiency treatment, diagnosis, staging, causes, types, symptoms. Information and current news about clinical trials and trial-related data, Glucose 6 Phosphate Dehydrogenase Deficiency prevention, screening, research, statistics and other Glucose 6 Phosphate Dehydrogenase Deficiency related topics. We answer all your qestions about Glucose 6 Phosphate Dehydrogenase Deficiency.

Question: What are the causes and effects of Glucose-6-Phosphate Dehydrogenase Deficiency?

Answer: Glucose-6-phosphatase dehydrogenase (G-6-PD) deficiency is the most common disease-producing enzymopathy in humans. Inherited as an X-linked disorder, G-6-PD deficiency affects 400 million people worldwide. The disease is highly polymorphic, with more than 300 reported variants. It confers protection against malaria, which probably accounts for its high gene frequency. The G6PD enzyme catalyzes the oxidation of glucose-6-phosphate to 6-phosphogluconate while concomitantly reducing the oxidized form of nicotinamide adenine dinucleotide phosphate (NADP+) to nicotinamide adenine dinucleotide phosphate (NADPH). NADPH, a required cofactor in many biosynthetic reactions, maintains glutathione in its reduced form. Reduced glutathione acts as a scavenger for dangerous oxidative metabolites in the cell. With the help of the enzyme glutathione peroxidase, reduced glutathione also converts harmful hydrogen peroxide to water. Red blood cells rely heavily upon G-6-PD activity because it is the only source of NADPH that protects the cells against oxidative stresses; therefore, people deficient in G-6-PD are not prescribed oxidative drugs because their red blood cells undergo rapid hemolysis under this stress. The five classes of G-6-PD deficiency include low, normal, or increased levels of the enzyme. Frequency: Internationally: The highest prevalence rates (with gene frequencies from 5-25%) are found in tropical Africa, the Middle East, tropical and subtropical Asia, some areas of the Mediterranean, and Papua New Guinea. Mortality/Morbidity: The most common clinical feature is a lack of symptoms. Symptomatic patients present with neonatal jaundice and acute hemolytic anemia. Neonatal jaundice: Jaundice usually appears by age 1-4 days, at the same time as or slightly earlier than so-called physiological jaundice and later than in-blood group alloimmunization. Kernicterus is a rare complication. Acute hemolytic anemia: Clinical expression results from stress factors such as oxidative drugs or chemicals, infection, or ingestion of fava beans. Race: G-6-PD deficiency affects all races. The highest prevalence is among persons of African, Asian, or Mediterranean descent. Severity varies significantly between racial groups because of different variants of the enzyme. Severe deficiency variants primarily occur in the Mediterranean population. The enzymatic variants in the African population have more activity and produce a milder form of the disease. Sex: G-6-PD deficiency is an X-linked inherited disease that primarily affects men. Homozygous women are found in populations in which the frequency of G-6-PD deficiency is quite high. Heterozygous (carrier) women can develop hemolytic attacks.


Glucose 6 Phosphate Dehydrogenase Deficiency News